Approval
FDA Approves Pebrilzo Biosimilar
The FDA approved Biocon's Pebrilzo, a Perjeta biosimilar, for use in specified combination regimens for HER2-positive early and metastatic breast cancer. A settlement and license agreement with Genentech permits the earliest licensed U.S. launch in the third quarter of 2028.
An EMA committee previously recommended European marketing authorization. Pebrilzo is Biocon's fifth FDA-approved oncology biosimilar.
Its boxed warnings include left ventricular dysfunction and embryo-fetal toxicity.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.